Search Results

Press Releases

Early Detection Of Breast Cancer Seen As A Benefit With Seated Option in the VELA Mammography Chair, Enable Me Finds in Technologist Survey

February 12, 2025

·

3 min read

Pharm Country

Vela Diagnostics Collaborates with SRL Inc. for Product Distribution in Japan

Vela Diagnostics announced a research collaboration with SRL Inc, a premier Japanese healthcare service company.

October 2, 2023

·

2 min read

MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa

MoonLake Immunotherapeutics today announced that the first patients have been screened at a U.S. trial site in its global Phase 3 clinical program, VELA, evaluating sonelokimab, an investigational Nanobody® designed to treat inflammatory disease, in patients with moderate-to-severe hidradenitis suppurativa (HS).

May 16, 2024

·

13 min read

Vela Diagnostics Develops PCR-based Test for Detecting Monkeypox Virus

Vela Diagnostics announced that it has developed a PCR test kit to detect the monkeypox virus, for research use only.

July 26, 2022

·

2 min read

Drug Development

Vela Diagnostics Supports COVID-19 Surveillance Efforts in Kenya

Vela Diagnostics has announced its appointment by the National Public Health Laboratory of Kenya as their supplier for SARS-CoV-2 genotyping tests, with funding from The Global Fund.

August 3, 2022

·

3 min read

Medical technology. Doctor holding health icon with dna, electronic medical record. Digital healthcare and research with global network connection on hologram virtual screen, insurance, digital health technology

Partnered

Ending the Diagnostic Odyssey for Patients

Ending the diagnostic journey for patients, particularly those with rare diseases, improves patients’ quality of life while reducing costs to healthcare systems.

December 11, 2024

·

4 min read

·

BioSpace Insights

Pharm Country

Vela Diagnostics Launches Multiplex PCR-Based Test for Detecting UTI Pathogens and Antimicrobial Resistance Genes

Vela Diagnostics announced today the launch of its new PathoKey® MP UTI ID and AMR PCR Test for research use only (RUO*).

May 17, 2022

·

3 min read

Drug Development

Blueprint Medicines Announces Lift of Partial Clinical Hold on Phase 1/2 VELA Trial of BLU-222

Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that the U.S. Food and Drug Administration (FDA) has lifted a partial clinical hold on the Phase 1/2 VELA trial of BLU-222.

March 28, 2023

·

5 min read

Drug Development

Blueprint Medicines Announces Partial Clinical Hold for Phase 1/2 VELA Trial of BLU-222

Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that the U.S. Food and Drug Administration (FDA) verbally informed the company on February 8, 2023 that it has placed a partial clinical hold on the Phase 1/2 VELA trial of BLU-222 due to visual adverse events (AEs) observed in a limited number of patients.

February 10, 2023

·

6 min read

Pharm Country

Media Pooling Strategy to Increase Testing Throughput Added to Vela Diagnostics’ ViroKey SARS-CoV-2 RT-PCR Test v2.0

Vela Diagnostics has announced that its ViroKey® SARS-CoV-2 RT-PCR Test v2.0 now has the additional capability to be used for pooling, using a three-in-one media pooling strategy.

April 22, 2022

·

2 min read